265 related articles for article (PubMed ID: 28165452)
21. The unique DEK oncoprotein in women's health: A potential novel biomarker.
de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
[TBL] [Abstract][Full Text] [Related]
22. DEK oncogene is overexpressed during melanoma progression.
Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
[TBL] [Abstract][Full Text] [Related]
23. Melanoma proliferation and chemoresistance controlled by the DEK oncogene.
Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS
Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545
[TBL] [Abstract][Full Text] [Related]
24. Dek overexpression in murine epithelia increases overt esophageal squamous cell carcinoma incidence.
Matrka MC; Cimperman KA; Haas SR; Guasch G; Ehrman LA; Waclaw RR; Komurov K; Lane A; Wikenheiser-Brokamp KA; Wells SI
PLoS Genet; 2018 Mar; 14(3):e1007227. PubMed ID: 29538372
[TBL] [Abstract][Full Text] [Related]
25. Long noncoding RNA SOX2OT maintains the stemness of pancreatic cancer cells by regulating DEK via interacting with miR-200a/141.
Liu CS; Zhou Q; Zhang YD; Fu Y
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2368-2379. PubMed ID: 32196588
[TBL] [Abstract][Full Text] [Related]
26. Role of the DEK oncogene in the development of squamous cell carcinoma.
Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
[TBL] [Abstract][Full Text] [Related]
27. A role for intracellular and extracellular DEK in regulating hematopoiesis.
Capitano ML; Broxmeyer HE
Curr Opin Hematol; 2017 Jul; 24(4):300-306. PubMed ID: 28306668
[TBL] [Abstract][Full Text] [Related]
28. Promotion of cell proliferation by the proto-oncogene DEK enhances oral squamous cell carcinogenesis through field cancerization.
Nakashima T; Tomita H; Hirata A; Ishida K; Hisamatsu K; Hatano Y; Kanayama T; Niwa A; Noguchi K; Kato K; Miyazaki T; Tanaka T; Shibata T; Hara A
Cancer Med; 2017 Oct; 6(10):2424-2439. PubMed ID: 28834425
[TBL] [Abstract][Full Text] [Related]
29. Inflammation: Hit the DEK!
Onuora S
Nat Rev Rheumatol; 2017 Apr; 13(4):196-197. PubMed ID: 28228649
[No Abstract] [Full Text] [Related]
30. DEK-AFF2 fusion-associated papillary squamous cell carcinoma of the sinonasal tract: clinicopathologic characterization of seven cases with deceptively bland morphology.
Kuo YJ; Lewis JS; Zhai C; Chen YA; Chernock RD; Hsieh MS; Lan MY; Lee CK; Weinreb I; Hang JF
Mod Pathol; 2021 Oct; 34(10):1820-1830. PubMed ID: 34108636
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-138 promotes neuroblastoma SH-SY5Y cell apoptosis by directly targeting DEK in Alzheimer's disease cell model.
Miao J; Jing J; Shao Y; Sun H
BMC Neurosci; 2020 Jul; 21(1):33. PubMed ID: 32736520
[TBL] [Abstract][Full Text] [Related]
32.
Panagopoulos I; Gorunova L; Torkildsen S; Tjønnfjord GE; Micci F; Heim S
Cancer Genomics Proteomics; 2017; 14(6):437-443. PubMed ID: 29109093
[TBL] [Abstract][Full Text] [Related]
33. Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides.
Forero L; Zwirner NW; Fink CW; Fernández-Viña MA; Stastny P
Hum Immunol; 1998 Jul; 59(7):443-50. PubMed ID: 9684994
[TBL] [Abstract][Full Text] [Related]
34. DEK over-expression promotes mitotic defects and micronucleus formation.
Matrka MC; Hennigan RF; Kappes F; DeLay ML; Lambert PF; Aronow BJ; Wells SI
Cell Cycle; 2015; 14(24):3939-53. PubMed ID: 25945971
[TBL] [Abstract][Full Text] [Related]
35. The nuclear DEK interactome supports multi-functionality.
Smith EA; Krumpelbeck EF; Jegga AG; Prell M; Matrka MM; Kappes F; Greis KD; Ali AM; Meetei AR; Wells SI
Proteins; 2018 Jan; 86(1):88-97. PubMed ID: 29082557
[TBL] [Abstract][Full Text] [Related]
36. Autoantibodies to DEK oncoprotein in systemic lupus erythematosus (SLE).
Wichmann I; Respaldiza N; Garcia-Lozano JR; Montes M; Sanchez-Roman J; Nuñez-Roldan A
Clin Exp Immunol; 2000 Mar; 119(3):530-2. PubMed ID: 10691927
[TBL] [Abstract][Full Text] [Related]
37. In silico gene expression and pathway analysis of DEK in the human brain across the lifespan.
Greene AN; Nguyen ET; Paranjpe A; Lane A; Privette Vinnedge LM; Solomon MB
Eur J Neurosci; 2022 Sep; 56(6):4720-4743. PubMed ID: 35972263
[TBL] [Abstract][Full Text] [Related]
38. Intercellular trafficking of the nuclear oncoprotein DEK.
Saha AK; Kappes F; Mundade A; Deutzmann A; Rosmarin DM; Legendre M; Chatain N; Al-Obaidi Z; Adams BS; Ploegh HL; Ferrando-May E; Mor-Vaknin N; Markovitz DM
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6847-52. PubMed ID: 23569252
[TBL] [Abstract][Full Text] [Related]
39. IRAK1 is a novel DEK transcriptional target and is essential for head and neck cancer cell survival.
Adams AK; Bolanos LC; Dexheimer PJ; Karns RA; Aronow BJ; Komurov K; Jegga AG; Casper KA; Patil YJ; Wilson KM; Starczynowski DT; Wells SI
Oncotarget; 2015 Dec; 6(41):43395-407. PubMed ID: 26527316
[TBL] [Abstract][Full Text] [Related]
40. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer.
Fu GK; Grosveld G; Markovitz DM
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1811-5. PubMed ID: 9050861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
